Review| Volume 45, ISSUE 3, P360-364, February 2009

Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer

Published:January 09, 2009DOI:


      The experience of synthesising a novel gastrin receptor antagonist gastrazole and taking it into 3 small clinical studies in pancreatic cancer in man is described. The need for such a compound is illustrated by the observation that inhibition of gastric acid secretion by H2 receptor antagonists results in hypergastrinaemia. A large number of cell types have gastrin receptors including pancreatic cancer cells which have been shown to be stimulated by gastrin. Small numbers of pancreatic cancer patients given gastrazole by continuous intravenous infusion showed prolonged survival compared with best supportive care or placebo, and equivalent survival to those given 5 fluouracil. The results suggest a greater benefit for patients with early stage disease. An alternative gastrin receptor antagonist YF 476 is also described which has the advantage of efficacy given by the oral route. This new compound requires to be studied in pancreatic cancer and other diseases associated with hypergastrinaemia.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Qvigstad G.
        • Waldum H.
        Rebound hypersecretion after inhibition of gastric acid secretion.
        Basic Clin Pharmacol Toxicol. 2004; 94: 202-208
        • Black J.W.
        • Kalindjian S.B.
        Gastrin agonists and antagonists.
        Pharmacol Toxicol. 2002; 91: 275-281
        • Smith J.P.
        • Fantaskey P.
        • Liu G.
        • Zagon S.
        Identification of gastrin as a growth peptide in human pancreatic cancer.
        Am J Physiol. 1995; 268: R135-R141
        • Henaghan M.A.
        • Hull R.A.D.
        • Kane P.
        • et al.
        Use of a novel CCKB/gastrin receptor antagonist, gastrazole (JB95008), in patients with advanced pancreatic adenocarcinoma. Results of an open-labelled pilot trial.
        Gastroenterology. 2001; 120: 3108
        • Chau I.
        • Cunningham D.
        • Russell C.
        • et al.
        Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.
        Brit J Cancer. 2006; 94: 1107-1115
        • Brett B.T.
        • Smith S.C.
        • Bouvier C.V.
        • et al.
        Phase II study of anti-gastrin-17 antibodies, raised to G17DT in advanced pancreatic cancer.
        J Clin Oncol. 2002; 20: 4225-4231
        • Takinami Y.
        • Yuki H.
        • Nishida A.
        • et al.
        YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.
        Aliment Pharmacol Ther. 1997; 11: 113-120
        • Boyce M.
        • Warrington S.
        • Johnston A.
        • Harris A.
        Effect on gastric pH of repeated doses of YF476, a new gastrin antagonist, compared with omeprazole and placebo.
        Brit J Clin Pharmacol. 2000; 49: 383-384
        • Boyce M.
        • Warrington S.
        • Nentwich H.
        • Norris V.
        • Hull R.
        • Black J.
        Effect of repeated doses of YF476, a gastrin antagonist, on pentagastrin-induced changes in volume, H+ content and pH of gastric aspirate in healthy subjects.
        Brit J Clin Pharmacol. 2004; 57: 684